(Q37328280)

19 August 2017

1 reference

title

Disease-modifying agents for multiple sclerosis: recent advances and future prospects (English)

1 reference

19 August 2017

0 references

10

Hans-Peter Hartung

1 reference

19 August 2017

11

Olaf Stüve

1 reference

19 August 2017

4

Bernd C Kieseier

1 reference

Hans-Christian von Büdingen

19 August 2017

object named as

Hans-Christian von Büdingen

5

1 reference

ORCID Public Data File 2021

author name string

Til Menge

1

1 reference

19 August 2017

Martin S Weber

2

1 reference

19 August 2017

Bernhard Hemmer

3

1 reference

19 August 2017

Clemens Warnke

6

1 reference

19 August 2017

Scott S Zamvil

7

1 reference

19 August 2017

Aaron Boster

8

1 reference

19 August 2017

Omar Khan

9

1 reference

19 August 2017

language of work or name

1 reference

1 January 2008

1 reference

19 August 2017

1 reference

19 August 2017

68

1 reference

19 August 2017

2445-2468

1 reference

19 August 2017

17

1 reference

https://scigraph.springernature.com/pub.10.2165/0003495-200868170-00004

19 August 2017

0 references

cites work

Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

An open label study of the effects of rituximab in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

An open trial of OKT3 in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0003495-200868170-00004

The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study

21 January 2018

1 reference

12 December 2020

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Suppression of experimental autoimmune neuritis by leflunomide

1 reference

12 December 2020

A full genome search in multiple sclerosis

1 reference

12 December 2020

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

1 reference

12 December 2020

Skin cancer in people with multiple sclerosis: a record linkage study

1 reference

12 December 2020

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis--the plaque and its pathogenesis

1 reference

12 December 2020

Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation.

1 reference

12 December 2020

Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis.

1 reference

12 December 2020

Infectious causes of multiple sclerosis

1 reference

12 December 2020

Amantadine for fatigue in multiple sclerosis

1 reference

12 December 2020

Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis

1 reference

12 December 2020

Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy.

1 reference

12 December 2020

Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis

1 reference

12 December 2020

Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.

1 reference

12 December 2020

Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group.

1 reference

12 December 2020

Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

1 reference

12 December 2020

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

12 December 2020

Notch receptor activation inhibits oligodendrocyte differentiation.

1 reference

12 December 2020

Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

12 December 2020

The promise of minocycline in neurology.

1 reference

12 December 2020

B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions

1 reference

12 December 2020

Humanized mouse models for organ-specific autoimmune diseases

1 reference

12 December 2020

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

1 reference

12 December 2020

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

1 reference

12 December 2020

Metalloproteinases: mediators of pathology and regeneration in the CNS.

1 reference

12 December 2020

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

12 December 2020

Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease

1 reference

12 December 2020

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

12 December 2020

Homogeneity of active demyelinating lesions in established multiple sclerosis

1 reference

12 December 2020

Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis.

1 reference

12 December 2020

Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?

1 reference

12 December 2020

Remyelination in demyelinating disease

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

1 reference

12 December 2020

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

1 reference

12 December 2020

Interferon-beta: mechanism of action and dosing issues

1 reference

12 December 2020

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network

1 reference

12 December 2020

The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.

1 reference

12 December 2020

Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases

1 reference

12 December 2020

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Treatment of active secondary progressive multiple sclerosis with treosulfan

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity

1 reference

12 December 2020

Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice

1 reference

12 December 2020

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

1 reference

12 December 2020

The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders

1 reference

12 December 2020

Experimental models of neuroprotection relevant to multiple sclerosis

1 reference

12 December 2020

Pathogenesis of axonal and neuronal damage in multiple sclerosis

1 reference

12 December 2020

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

12 December 2020

Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro

1 reference

12 December 2020

Is it clinically relevant to repair focal multiple sclerosis lesions?

1 reference

12 December 2020

Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord

1 reference

12 December 2020

Axonal protection achieved in a model of multiple sclerosis using lamotrigine

1 reference

12 December 2020

Apoptotic effects of Human Herpesvirus-6A on glia and neurons as potential triggers for central nervous system autoimmunity

1 reference

12 December 2020

Substance P receptor mediated maintenance of chronic inflammation in EAE

1 reference

12 December 2020

B cells move to centre stage: novel opportunities for autoimmune disease treatment

1 reference

12 December 2020

The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells.

1 reference

12 December 2020

Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice

1 reference

12 December 2020

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.

1 reference

12 December 2020

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

12 December 2020

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients

1 reference

12 December 2020

Central nervous system infections - a potential complication of systemic immunotherapy

1 reference

12 December 2020

Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration

1 reference

12 December 2020

Interferon-beta1a for the treatment of multiple sclerosis

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

Migratory Activity and Functional Changes of Green Fluorescent Effector Cells before and during Experimental Autoimmune Encephalomyelitis

1 reference

12 December 2020

Therapeutic potential of gamma-secretase inhibitors and modulators

1 reference

12 December 2020

Targeting MMPs in acute and chronic neurological conditions

1 reference

12 December 2020

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

12 December 2020

Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation.

1 reference

12 December 2020

A pathogenic role for CD8+ T cells in a spontaneous model of demyelinating disease

1 reference

12 December 2020

MMPs in the central nervous system: where the good guys go bad.

1 reference

12 December 2020

The prevalence of multiple sclerosis in the world: an update

1 reference

12 December 2020

Dimethylfumarate is a potent inducer of apoptosis in human T cells

1 reference

12 December 2020

Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis

1 reference

12 December 2020

The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.

1 reference

12 December 2020

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

1 reference

12 December 2020

"Viral déjà vu" elicits organ-specific immune disease independent of reactivity to self

1 reference

12 December 2020

Multiple sclerosis: disease biomarkers as indicated by pathophysiology

1 reference

12 December 2020

Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells.

1 reference

12 December 2020

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

1 reference

12 December 2020

Remyelination is extensive in a subset of multiple sclerosis patients.

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

12 December 2020

Basic principles of immunological surveillance of the normal central nervous system

1 reference

12 December 2020

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

The mechanism of inhibition of experimental allergic encephalomyelitis in the rat by monoclonal antibody against CD4.

1 reference

12 December 2020

1 reference

12 December 2020

Efficient central nervous system remyelination requires T cells.

1 reference

12 December 2020

Pharmacological treatment of early multiple sclerosis

1 reference

12 December 2020

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

12 December 2020

Biological markers in CSF and blood for axonal degeneration in multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial

1 reference

12 December 2020

Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

1 reference

12 December 2020

An APRIL to remember: novel TNF ligands as therapeutic targets

1 reference

12 December 2020

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

1 reference

12 December 2020

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

1 reference

12 December 2020

The role of MRI as a surrogate outcome measure in multiple sclerosis

1 reference

12 December 2020

Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment

1 reference

12 December 2020

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

1 reference

12 December 2020

Glutamate excitotoxicity in a model of multiple sclerosis

1 reference

12 December 2020

Treatment of multiple sclerosis with the pregnancy hormone estriol

1 reference

12 December 2020

The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system

1 reference

12 December 2020

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

12 December 2020

Therapeutic role of mitoxantrone in multiple sclerosis

1 reference

12 December 2020

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

1 reference

12 December 2020

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

1 reference

12 December 2020

Three or more routes for leukocyte migration into the central nervous system

1 reference

12 December 2020

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

1 reference

12 December 2020

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Clinical trials in multiple sclerosis: methodological issues

1 reference

12 December 2020

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

1 reference

12 December 2020

The role of B cells and autoantibodies in multiple sclerosis

1 reference

12 December 2020

Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.

1 reference

12 December 2020

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions

1 reference

12 December 2020

A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS.

1 reference

12 December 2020

Primary-progressive multiple sclerosis

1 reference

12 December 2020

Molecular and biochemical pharmacology of mitoxantrone

1 reference

12 December 2020

Genetics of multiple sclerosis

1 reference

12 December 2020

The treatment of chronic progressive multiple sclerosis with cladribine

1 reference

12 December 2020

Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection

1 reference

12 December 2020

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

1 reference

12 December 2020

A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis

1 reference

12 December 2020

Neurodegeneration: a failure of neuroregeneration?

1 reference

12 December 2020

B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus

1 reference

12 December 2020

The role of optical coherence tomography in multiple sclerosis: expert panel consensus

1 reference

12 December 2020

LINGO-1 negatively regulates myelination by oligodendrocytes

1 reference

12 December 2020

The expression and function of chemokines involved in CNS inflammation

1 reference

12 December 2020

Why does remyelination fail in multiple sclerosis?

1 reference

12 December 2020

Mechanism of action of glatiramer acetate in treatment of multiple sclerosis

1 reference

12 December 2020

Autologous haematopoietic-stem-cell transplantation for multiple sclerosis

1 reference

12 December 2020

Azathioprine for multiple sclerosis

1 reference

12 December 2020

A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis

1 reference

12 December 2020

A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Overcoming failure to repair demyelination in EAE: gamma-secretase inhibition of Notch signaling

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Immune control by endocannabinoids - new mechanisms of neuroprotection?

1 reference

12 December 2020

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin

1 reference

12 December 2020

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

A specific viral cause of multiple sclerosis: one virus, one disease

1 reference

12 December 2020

Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis

1 reference

12 December 2020

Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.

1 reference

12 December 2020

A recombinant human IgM promotes myelin repair after a single, very low dose

1 reference

12 December 2020

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

12 December 2020

Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression

1 reference

12 December 2020

Glutamate inhibition in MS: the neuroprotective properties of riluzole

1 reference

12 December 2020

Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion

1 reference

12 December 2020

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

12 December 2020

Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis

1 reference

12 December 2020

Campath-1H treatment of multiple sclerosis

1 reference

12 December 2020

Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist--a putative role for substance P in CNS inflammation.

1 reference

12 December 2020

Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis

1 reference

12 December 2020

A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor

1 reference

12 December 2020

New concepts in the immunopathogenesis of multiple sclerosis

1 reference

12 December 2020

Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes

1 reference

12 December 2020

Dual role of inflammation in CNS disease

1 reference

12 December 2020

Multiple pathways to induction of virus-induced autoimmune demyelination: lessons from Theiler's virus infection

1 reference

12 December 2020

Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

The adhesion molecule and cytokine profile of multiple sclerosis lesions

1 reference

12 December 2020

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis

1 reference

12 December 2020

Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab

1 reference

12 December 2020

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

12 December 2020

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

12 December 2020

A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2

1 reference

12 December 2020

The B cell--old player, new position on the team

1 reference

12 December 2020

Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation

1 reference

12 December 2020

Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies

1 reference

12 December 2020

Inhibition of autoimmune encephalomyelitis by a tetracycline.

1 reference

12 December 2020

Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2

1 reference

12 December 2020

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

1 reference

12 December 2020

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

1 reference

12 December 2020

Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis

1 reference

12 December 2020

Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis.

1 reference

12 December 2020

Choosing drug therapy for multiple sclerosis. An update.

1 reference

12 December 2020

B cells: no longer the nondominant arm of multiple sclerosis.

1 reference

12 December 2020

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

12 December 2020

Immunoglobulins promote remyelination in the central nervous system

1 reference

12 December 2020

Cancer risk among patients with multiple sclerosis: a population-based register study

1 reference

12 December 2020

Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.

1 reference

12 December 2020

Clonal Accumulation of Activated CD8+T Cells in the Central Nervous System during the Early Phase of Neuroborreliosis

1 reference

12 December 2020

Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis

1 reference

12 December 2020

Immunosuppressive treatment in multiple sclerosis

1 reference

12 December 2020

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.

1 reference

12 December 2020

Immunosuppression: promises and failures

1 reference

12 December 2020

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

1 reference

12 December 2020

Epitope spreading in immune-mediated diseases: implications for immunotherapy

1 reference

12 December 2020

Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4

1 reference

12 December 2020

Targeting leukocyte integrins in human diseases

1 reference

12 December 2020

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

1 reference

12 December 2020

Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.

1 reference

12 December 2020

The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion.

1 reference

12 December 2020

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

1 reference

12 December 2020

The therapeutic potential of neural stem cells

1 reference

12 December 2020

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

1 reference

12 December 2020

Risk alleles for multiple sclerosis identified by a genomewide study

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

Immune surveillance in multiple sclerosis patients treated with natalizumab.

1 reference

12 December 2020

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

1 reference

12 December 2020

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician

1 reference

12 December 2020

Management of multiple sclerosis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

1 reference

12 December 2020

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

1 reference

12 December 2020

1 reference

12 December 2020

Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction

1 reference

12 December 2020

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

1 reference

12 December 2020

A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group

1 reference

12 December 2020

A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses

1 reference

12 December 2020

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis

1 reference

12 December 2020

Statins--a cure-all for the brain?

1 reference

12 December 2020

Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis

1 reference

12 December 2020

Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1

1 reference

12 December 2020

The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β

1 reference

12 December 2020

Clinical characteristics of progressive relapsing multiple sclerosis

1 reference

12 December 2020

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

1 reference

12 December 2020

Environmental risk factors for multiple sclerosis. Part I: The role of infection

1 reference

12 December 2020

Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.

1 reference

12 December 2020

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

1 reference

12 December 2020

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

12 December 2020

Symptomatic therapy and neurorehabilitation in multiple sclerosis

1 reference

12 December 2020

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

12 December 2020

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

1 reference

12 December 2020

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

1 reference

12 December 2020

The immunopathology of multiple sclerosis: an overview

1 reference

12 December 2020

Viral induced demyelination

1 reference

12 December 2020

Multiple sclerosis in 54 twinships: concordance rate is independent of zygosity. French Research Group on Multiple Sclerosis

1 reference

12 December 2020

Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis

1 reference

12 December 2020

The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.

1 reference

12 December 2020

10.2165/0003495-200868170-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

19 August 2017

0 references

1 reference